Abstract
Approximately 4% of non-small-cell lung cancers (NSCLC), mostly adenocarcinomas, harbor oncogenic ALK gene fusions. Patients with such ALK-positive NSCLC tend to be younger, more frequently female and more frequently non-smokers (1,2). Based on superiority to chemotherapy two ALK-tyrosine kinase inhibitors crizotinib (3) and ceritinib (4) were approved for first-line therapy. Hence, both ESMO (5) and CAP (6) guidelines require screening of all NSCLC for ALK fusions, except pure squamous cell carcinomas from heavy smokers. As rapid and cost-effective screening by IHC followed by either by FISH or hybrid capture sequencing has been established, even in patients presenting with very advanced disease and urgent need for therapy first line therapies are possible and effective (7). An illustrative case is shown in Figure 1 and presented in detail previously (7).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
